An observational study in Peri Implantitis and Peri Implant Mucositis, sponsored by Recep Tayyip Erdogan University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Recep Tayyip Erdogan University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Peri-Implantitis with a site in Turkey — 16 open to participants now, 19 under way, none of them phase 3. Peri-Implantitis · Turkey.
Among the 55 studies in Peri-Implantitis with a site in Turkey, this one is the 17th largest by planned enrollment of the 29 observational ones that give a count, is one of 8 that started in 2025, is one of 29 observational ones, reaches primary completion later than 16 of the 18 other live ones, and was the 37th registered.
324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.
Browse Peri-Implantitis studies →16 of the 55 studies in Peri-Implantitis with a site in Turkey are open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18+ · Healthy volunteers
Kübra Hazal Bilgin · Sites in Turkey
Ages 45+ · Women only
Gazi University · Sites in Turkey
Ages 21–75 · Healthy volunteers
Gazi University · Sites in Turkey
Ages 18–75 · Healthy volunteers
Biruni University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 8 started in 2025.
This study's planned enrollment of 72 is below the median of 84 across 122 observational studies indexed under Peri-Implantitis.
Median enrollment 50 across the 26 interventional studies, 87 across the 29 observational. Of the 34 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 55 has an industry lead sponsor. The 10 most frequent:
Recep Tayyip Erdogan University is the lead sponsor of 69 studies on the registry; 13 are open to participants now.
Recep Tayyip Erdogan University has 2 studies filed under Peri-Implantitis — fewer than ten, so there is no comparison to draw.
8 of the studies in Peri-Implantitis with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06830200Hacettepe UniversityPeri-implantitis Treatment With Chitosan Brush | 2026-12-01 |
| NCT07907900Ankara UniversityDiagnostic Accuracy of Large Language Models for Peri-Implant Marginal Bone Loss on Panoramic Radiographs | 2026-12-31 |
| NCT07785817Medipol UniversityEvaluation of aMMP-8 and IL-1β Levels and Marginal Bone Loss Associated With Peri-Implant Mucositis and Peri-Implantitis in Postmenopausal Women | 2027-02-01 |
| NCT07797127Adiyaman UniversityEvaluation of the Effects of Routine Phase I Periodontal Therapy on Clinical Parameters and Levels of Gremlin-1, CTHRC1, and Tenascin-C in Gingival Crevicular Fluid and Peri-Implant Sulcular Fluid in Individuals With Periodontitis and Peri-Implantitis | 2027-03-01 |
| NCT07471386Gazi UniversityAdjunctive Keratinized Mucosa Augmentation in Peri-Implantitis | 2027-04-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 55 studies in Peri-Implantitis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Despite technological advances that have significantly improved dental implant osseointegration and survival rates, biological complications such as peri-implantitis and peri-implant mucositis are common around the implant. The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), can be induced by the expression of leucine-lysine-37 (LL-37), a human antimicrobial peptide in the cathelicidin family. Studies have shown that 1,25(OH)2D3 and its precursor, 25(OH)D3, significantly reduce inflammation by suppressing the release of receptor activator nuclear factor kappa b ligand (RANKL), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, and IL-6, and by preventing alveolar bone loss. To date, many cytokines have been investigated in peri-implant sulcus fluid (PIOS). The lack of a direct study investigating vitamin D and LL-37 levels in PIOS constitutes the unique value of this project. This study aims to compare LL-37 and 25(OH)D3 levels in PIOS and examine their correlation with markers such as IL-6, IL-10, and MMP-8, as well as clinical parameters. Volunteers aged 18-65 who have received dental implants at the Recep Tayyip Erdoğan University Faculty of Dentistry and have been using their implant-supported prosthesis for at least one year and who have been informed about this study will be included in the study. The groups will be formed as peri-implant health, peri-implant mucositis, and peri-implantitis. The implants of the patients included in the study will be evaluated for probed pocket depth (PPD), clinical attachment level (CAL), suppuration (S), modified gingival index (mGI), plaque index (mPI), bleeding index (mBI), keratinized gingival amount, and attached gingival amount. PIOS and serum samples will be obtained from patients, and their relationship to periodontal status and each other will be statistically evaluated.
This project may help discover new biomarkers that can be used in the early diagnosis of peri-implantar diseases. This study could contribute to earlier treatment, lower patient costs, and even the development of new treatment plans for these diseases.
The G*Power analysis performed to determine the number of samples to be included in the study determined that a total of 72 samples/implants should be included, with a minimum of 24 in each group, when the power of the test was taken as 0.85, the effect size as 0.4, and the Type-1 error (α) as 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Criteria such as absence of clinical signs of inflammation in the tissues, absence of bleeding on probing, PPD ≤5.0 mm, and absence of bone loss greater than 2 mm after initial healing will be sought.
Criteria such as clinical signs of inflammation (erythema, swelling, suppuration) in the tissues, bleeding on probing, and an PPD of 5.0 mm will be sought. At the time of implant placement, the height of the surrounding soft tissue influences the initial probing depth.
Bleeding, inflammation, redness, edema, suppuration, and in addition to these, bone loss \>5 mm and radiographically observed in PPD are observed in the tissues.
Probing pocket depth (PPD)
The distance from the gingival margin to the pocket base around the implants was measured in mm using a periodontal probe, at six locations for each implant. The average value will be determined for each implant circumference.
Time frame: baseline
clinical attachment level (CAL)
Similar to the PPD measurement, this will be done by determining the distance between the pocket base and the implant neck.
Time frame: baseline
25-Hydroxy Vitamin D3 ((25(OH)D3))
25(OH)D3 levels in PIOS samples will be analyzed by ELISA or CMIA methods.
Time frame: baseline
leucine leucine-37 (LL-37)
LL-37 levels in PIOS samples will be evaluated by ELISA method.
Time frame: baseline
Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.
Of 33 non-industry observational studies under Peri-Implantitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 77. This study's planned 17 months is close to that.
Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 8 and three quarters within 77.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Apr 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Recep Tayyip Erdogan University